Emerging drugs for chronic hepatitis C.
Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. A combination therapy comprising pegylated interferon and ribavirin currently represents the most effective therapy for chronic HCV infection. The limitations of this current therapy mainly its efficacy and significant side effects have prompted the development of new drugs. Few categories of therapeutic agents appear promising for future therapy, e.g. novel interferons, ribavirin analogs, antisense oligonucleotides, short interfering RNAs, ribozymes, enzyme inhibitors, immunomodulatory agents, antifibrotic agents, therapeutic vaccines and antibodies. Few drugs belong to afore-mentioned categories have already reached the different clinical phases of development. The present article highlights the status of current available therapies and emerging drugs for the treatment of hepatitis C.
Bhopale
Girish Mahadeorao
GM
Research and Development Division, Hindustan Antibiotics Limited, Pimpri, Pune 411018, India.
Nanda
Rabindra Kumar
RK